LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/Heraeus: PALACOS Available Direct in U.S.
Large Joints and Extremities

Heraeus: PALACOS Available Direct in U.S.

January 19, 2018 1 min read Premium comments

Advertisement

Heraeus: PALACOS Available Direct in U.S.
PALACOS bone cement / Heraeus Medical
Secondary#knee#pain#hip

Hanau, Germany-based Heraeus Medical, inventor and manufacturer of PALACOS bone cement products, is announcing that is has begun selling these products direct in the U.S. through its affiliate Heraeus Medical LLC.

“The company is extremely excited about the opportunity to support total joint surgeons directly in the U.S. in providing consistent, predictable outcomes with the potential for lower revision rates,” said Dr. Andrew Williamson, Heraeus Medical board member, in the January 15, 2018 news release. Devin Childers, vice president and general manager of Heraeus Medical LLC, added, “The expertise and knowledge Heraeus Medical can directly offer its loyal PALACOS users in the U.S. creates an atmosphere of both continued innovation and collaboration.”

Dr. Williamson told OTW, “In an era of value-based care, we are most excited to collaborate with physicians and health systems on improving outcomes in joint replacement surgery. Internationally, Heraeus is a leader in joint fixation and periprosthetic infection management. Over the course of 2018, we are excited to introduce new products and our Palacademy education platforms to the U.S. market that enable the pursuit of value-based care. We also hope to engage in better and creative relationships with health systems and work with them on research that advances the care of orthopedic patients.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy